Stock Analysis on Net

UnitedHealth Group Inc. (NYSE:UNH)

Cash Flow Statement 
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

UnitedHealth Group Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Net earnings (loss) 218 2,543 3,572 6,474 5,784 6,258 4,421 (1,221) 5,675 6,038 5,657 5,774 4,908 5,384 5,199 5,148 4,191 4,191 4,372 4,978
Depreciation and amortization 1,117 1,099 1,084 1,061 1,041 1,041 1,020 997 974 1,007 1,021 970 982 828 802 788 771 796 778 758
Deferred income taxes (733) (932) (151) 64 (62) 124 (331) (27) 249 (12) (150) (332) (83) (575) (176) 161 (243) 46 (14) 341
Share-based compensation 176 223 197 375 187 237 222 372 208 247 242 362 250 171 205 299 209 165 170 256
Loss on sale of subsidiary and subsidiaries held for sale 126 83 41 15 (21) 20 1,225 7,086
Gains on dispositions and other strategic transactions (910) (3,333)
Other, net 1,609 (63) 30 97 582 (1,069) 280 179 (446) 32 (160) 69 (331) (215) 198 17 (749) 19 (159) (55)
Noncash items 1,385 410 1,201 1,612 (1,606) 353 2,416 8,607 985 1,274 953 1,069 818 209 1,029 1,265 (12) 1,026 775 1,300
Accounts receivable (829) 1,746 2,781 (4,462) (2,122) 3,156 3,691 (6,162) (540) (2,771) 4,503 (4,306) 40 1,641 317 (4,521) (153) 371 1,677 (2,895)
Other assets (1,501) (962) (1,599) (544) (1,152) 1,133 (2,194) (1,927) (86) (357) (126) (1,875) (633) (98) 446 (1,089) 404 88 (568) (955)
Medical costs payable (354) 1,807 1,378 2,993 268 1,458 (1,292) 2,069 (355) 1,429 (59) 2,467 (139) 163 180 3,849 (1,224) 839 118 2,968
Accounts payable and other liabilities 2,082 63 127 (607) 1,213 1,214 267 (231) 1,146 823 (249) 1,796 548 609 218 589 (9) 873 (572) 870
Unearned revenues 107 338 (272) (10) (16) 373 (563) 9 (12,018) 466 353 11,402 (10,075) 10,641 (518) 78 21 192 (262) (261)
Net change in other operating items, net of effects from acquisitions and dispositions (495) 2,992 2,415 (2,630) (1,809) 7,334 (91) (6,242) (11,853) (410) 4,422 9,484 (10,259) 12,956 643 (1,094) (961) 2,363 393 (273)
Cash flows from operating activities 1,108 5,945 7,188 5,456 2,369 13,945 6,746 1,144 (5,193) 6,902 11,032 16,327 (4,533) 18,549 6,871 5,319 3,218 7,580 5,540 6,005
Purchases of investments (4,568) (4,625) (4,045) (4,135) (7,357) (9,821) (5,332) (4,798) (5,316) (3,773) (4,331) (4,894) (4,642) (5,280) (3,921) (4,982) (4,312) (3,980) (4,235) (4,612)
Sales of investments 1,343 2,764 1,996 3,185 3,449 9,777 2,312 2,976 3,633 486 2,732 456 531 3,028 757 1,591 4,476 1,161 765 643
Maturities of investments 1,929 2,191 2,159 2,167 2,581 2,117 2,307 2,314 2,756 2,011 2,344 2,119 1,341 1,551 1,430 1,759 1,695 1,906 2,395 2,255
Cash paid for acquisitions and other transactions, net of cash assumed (73) (3,702) (32) (702) (1,734) (8,643) (25) (3,006) (1,747) (228) (335) (7,826) (14,304) (4) (5,919) (1,231) (94) (85) (3,449) (1,193)
Purchases of property, equipment and capitalized software (948) (890) (886) (898) (912) (991) (853) (743) (959) (838) (829) (760) (866) (724) (657) (555) (695) (629) (562) (568)
Loans to care providers, cyberattack (129) (804) (5,936) (2,164)
Repayments of care provider loans, cyberattack 137 250 402 891 1,325 2,585 604
Cash received from dispositions 561 2,041 685 3,414
Originations and purchases of loans (4,795)
Repayments and maturities of loans 1,980
Other, net 1,823 (546) (1,036) (582) (383) 129 (494) (919) (239) (297) (309) (115) (843) 582 (277) (255) (354) (252) (416) (232)
Cash flows used for investing activities (2,611) (4,558) (1,442) (74) (1,119) (5,651) (7,417) (6,340) (1,187) (2,639) (728) (11,020) (15,369) (847) (8,587) (3,673) 716 (1,879) (5,502) (3,707)
Common share repurchases (2,545) (3,000) (4,972) (956) (3,072) (1,500) (1,500) (3,000) (2,000) (1,000) (1,000) (2,500) (2,500) (1,050) (1,050) (1,250) (1,650)
Cash dividends paid (2,002) (2,002) (2,000) (1,912) (1,932) (1,937) (1,935) (1,729) (1,738) (1,739) (1,747) (1,537) (1,541) (1,542) (1,545) (1,363) (1,365) (1,367) (1,367) (1,181)
Proceeds from common stock issuances 24 222 221 360 235 867 258 486 314 411 284 344 169 328 205 551 278 313 328 436
Repayments of long-term debt (1,050) (2,000) (500) (750) (1,000) (750) (750) (1,375) (915) (1,000) (1,100) (1,250) (750) (1,150)
Proceeds from (repayments of) short-term borrowings, net (662) 2,872 (5,314) 3,911 40 (8,806) 2,426 6,189 (1,568) (1,847) (3,923) 7,349 748 (1,356) (1,808) 3,148 (1) (1,125) (4,233) 4,057
Proceeds from issuance of long-term debt 2,969 11,886 5,925 (7) 6,401 8,897 5,922 (1) 6,934
Customer funds administered 2,158 (1,767) (1,270) 1,245 (501) (2,049) (755) 1,745 (2,558) (2,032) (943) 5,012 (1,480) 1,242 666 5,120 (780) (993) 264 2,131
Purchases of redeemable noncontrolling interests (165) (280) (730) (79) (97) (1,338)
Other, net 666 (90) (8) (505) (432) (460) (190) (563) 624 (397) (373) (1,004) (486) (9) 103 (1,552) 542 (175) 1,194 (1,856)
Cash flows from (used for) financing activities (1,031) (2,765) (7,947) 99 (8,342) (2,205) (1,196) 8,231 (7,156) (7,104) (10,459) 13,190 4,392 (3,416) 946 2,304 (3,627) (4,397) (218) 787
Effect of exchange rate changes on cash and cash equivalents 15 (4) 14 15 (31) 14 4 (48) 48 (57) 55 51 30 (53) (100) 157 (17) (51) 57 (51)
Increase (decrease) in cash and cash equivalents, including cash within businesses held for sale (2,519) (1,382) (2,187) 5,496 (7,123) 6,103 (1,863) 2,987 (13,488) (2,898) (100) 18,548 (15,480) 14,233 (870) 4,107 290 1,253 (123) 3,034
Net increase (decrease) in cash within businesses held for sale (326) (4) 66 (91) 35 11 (265)
Net increase (decrease) in cash and cash equivalents (2,845) (1,386) (2,121) 5,405 (7,088) 6,114 (2,128) 2,987 (13,488) (2,898) (100) 18,548 (15,480) 14,233 (870) 4,107 290 1,253 (123) 3,034

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The cash flow statement reveals significant fluctuations across the observed period, spanning from March 2021 to December 2025. Overall cash flow from operating activities demonstrates considerable variability, with notable peaks and troughs. A period of strong positive operating cash flow is evident through September 2023, followed by a substantial decline and negative cash flow in the subsequent quarters.

Net Earnings and Noncash Adjustments
Net earnings exhibit a generally increasing trend from 2021 to September 2023, peaking at $6,038 million, before experiencing a dramatic decrease to a loss of $1,221 million in March 2024. Noncash items, including depreciation, amortization, share-based compensation, and deferred income taxes, consistently contribute positively to cash flow from operations, with a general upward trend in these adjustments over time. However, the impact of deferred income taxes is highly variable, swinging between positive and negative values.
Working Capital Dynamics
Changes in working capital components demonstrate substantial volatility. Accounts receivable show significant fluctuations, often negatively impacting cash flow, particularly in the earlier periods and again in March 2024. Medical costs payable and accounts payable generally contribute positively to cash flow, though with considerable quarterly variation. Unearned revenues exhibit particularly large swings, with a massive inflow in September 2022 ($10,641 million) followed by a substantial outflow in December 2022 (-$10,075 million), indicating potentially significant timing differences in revenue recognition. Other operating items also display large and inconsistent changes.
Investing Activities
Cash flows used for investing activities are consistently negative, primarily driven by purchases of investments and property, equipment, and capitalized software. Purchases of investments represent a substantial outflow throughout the period. Significant activity related to acquisitions, including substantial cash outlays in March 2024 ($7,086 million) and June 2024 ($1,225 million), and related dispositions are observed. The company also engages in lending activities to care providers, with associated repayments.
Financing Activities
Cash flows from financing activities are highly variable. Common share repurchases consistently represent a significant cash outflow, although they are absent in some quarters. Cash dividends paid also contribute to consistent negative cash flow. The company utilizes both debt issuance and repayment, with notable debt issuances in June 2021 ($6,934 million) and June 2022 ($5,922 million). Customer funds administered represent a significant and fluctuating component of financing cash flows, with substantial inflows and outflows throughout the period.
Overall Cash Position
The increase or decrease in cash and cash equivalents mirrors the volatility observed in operating and financing activities. Periods of strong positive operating cash flow, such as through September 2023, generally coincide with increases in cash. Conversely, the negative operating cash flow in late 2023 and 2024, coupled with significant investing and financing outflows, resulted in substantial decreases in the cash balance. Exchange rate changes have a relatively minor impact on cash flow.

The company’s cash flow profile is characterized by substantial variability, driven by fluctuations in net earnings, working capital, investing activities related to acquisitions and investments, and financing activities involving share repurchases, debt management, and customer funds. The dramatic shift to a net loss in March 2024 significantly impacted operating cash flow and overall liquidity.

AI Ask an analyst for more